X0306 4 2021-08-03 0 0001770787 10x Genomics, Inc. TXG 0001786720 Saxonov Serge C/O 10X GENOMICS, INC. 6230 STONERIDGE MALL ROAD PLEASANTON CA 94588 1 1 0 0 Chief Executive Officer Class A Common Stock 2021-08-03 4 M 0 5208 5.04 A 909276 D Class A Common Stock 2021-08-03 4 M 0 9792 11.48 A 919068 D Class A Common Stock 2021-08-03 4 S 0 1700 176.5203 D 917368 D Class A Common Stock 2021-08-03 4 S 0 4450 177.5574 D 912918 D Class A Common Stock 2021-08-03 4 S 0 7946 178.4706 D 904972 D Class A Common Stock 2021-08-03 4 S 0 904 179.3464 D 904068 D Class A Common Stock 89960 I See Footnote Stock Option (right to buy) 5.04 2021-08-03 4 M 0 5208 0.00 D 2028-11-02 Class A Common Stock 5208 74157 D Stock Option (right to buy) 11.48 2021-08-03 4 M 0 9792 0.00 D 2029-05-10 Class A Common Stock 9792 67921 D The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. This transaction was executed in multiple trades at prices ranging from $175.995 to $176.98. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $177.00 to $177.98. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $178.00 to $178.99. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $179.03 to $179.98. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee. This option, originally for 250,000 shares, of which 175,843 have been exercised, vested as to one forty-eighth of the shares on October 1, 2018, and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. This option, originally for 145,786 shares, of which 77,865 have been exercised, vested as to one forty-eighth of the shares on May 1, 2019, and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. /s/ Eric S. Whitaker, as Attorney-in-Fact 2021-08-04